

Kaleb Michaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4957346/publications.pdf>

Version: 2024-02-01

191
papers

13,883
citations

23567
58
h-index

22166
113
g-index

196
all docs

196
docs citations

196
times ranked

11908
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. <i>Arthritis Care and Research</i> , 2023, 75, 231-239.	3.4	6
2	Reduction of Cardiovascular Disease and Mortality Versus Risk of New-Onset Diabetes Mellitus With Statin Use in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 597-607.	3.4	7
3	Knee joint unloading and daily physical activity associate with cartilage T2 relaxation times 1 month after ACL injury. <i>Journal of Orthopaedic Research</i> , 2022, 40, 138-149.	2.3	13
4	Increase in Cannabis Use Among Adults With Rheumatic Diseases: Results From a 2014–2019 United States Observational Study. <i>Arthritis Care and Research</i> , 2022, 74, 2091-2099.	3.4	10
5	Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs. <i>Rheumatology and Therapy</i> , 2022, 9, 1091-1107.	2.3	1
6	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2022, 74, 1399-1408.	3.4	21
7	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Arthritis and Rheumatology</i> , 2022, 74, 1464-1473.	5.6	12
8	Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. <i>Arthritis Care and Research</i> , 2021, 73, 1809-1814.	3.4	22
9	Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration. <i>Arthritis Care and Research</i> , 2021, 73, 1363-1371.	3.4	15
10	Obesity and the Risk of Incident Chronic Opioid Use in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1405-1412.	3.4	9
11	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	3.4	35
12	Defining Pain That Does Not Interfere With Activities Among Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2021, 73, 626-632.	3.4	4
13	Acceptability and Content Validity of Patient-Reported Outcome Measures Considered From the Perspective of Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 510-519.	3.4	6
14	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 286-292.	0.9	35
15	Self-Management of Rheumatoid Arthritis: Mobile Applications. <i>Current Rheumatology Reports</i> , 2021, 23, 2.	4.7	15
16	The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 648-655.	2.0	56
17	Driving Ability and Safety in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 489-497.	3.4	8
18	The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE). <i>ACR Open Rheumatology</i> , 2021, 3, 221-230.	2.1	4

#	ARTICLE	IF	CITATIONS
19	Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. <i>Arthritis and Rheumatology</i> , 2021, 73, 2179-2188.	5.6	89
20	Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1421-1429.	5.6	19
21	Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?. <i>RMD Open</i> , 2021, 7, e001618.	3.8	12
22	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021, 41, 1755-1761.	3.0	12
23	Vehicle Control as a Measure of Real-World Driving Performance in Patients with Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, , .	3.4	2
24	Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. <i>Arthritis Care and Research</i> , 2021, 73, 1322-1331.	3.4	12
25	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 1510-1518.	3.9	18
26	OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies. <i>PLoS ONE</i> , 2021, 16, e0245598.	2.5	6
27	Response to: "Association of proton pump inhibitors with fracture risk in patients with rheumatoid arthritis" by Sugiyama. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e111-e111.	0.9	0
28	Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 798-805.	3.4	6
29	Changes in Alcohol Use and Associations With Disease Activity, Health Status, and Mortality in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 301-308.	3.4	13
30	Development of Resilience Among Rheumatoid Arthritis Patients: A Qualitative Study. <i>Arthritis Care and Research</i> , 2020, 72, 1257-1265.	3.4	19
31	Measures of Rheumatoid Arthritis Disease Activity. <i>Arthritis Care and Research</i> , 2020, 72, 4-26.	3.4	9
32	Reply. <i>Arthritis Care and Research</i> , 2020, 72, 1340-1340.	3.4	0
33	Reply. <i>Arthritis Care and Research</i> , 2020, 72, 1509-1510.	3.4	0
34	Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 555-564.	2.1	4
35	Probiotic Use and Psoriatic Arthritis Disease Activity. <i>ACR Open Rheumatology</i> , 2020, 2, 330-334.	2.1	7
36	Defining Minimally Important Changes for the Patient Activity Scale-II. <i>Arthritis Care and Research</i> , 2020, 73, 1456-1460.	3.4	1

#	ARTICLE	IF	CITATIONS
37	Response to: “Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis” by Lai <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e157-e157.	0.9	0
38	Estimation of Minimally Important Differences and Patient Acceptable Symptom State Scores for the Patient-Reported Outcomes Measurement Information System Pain Interference Short Form in Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 320-329.	2.1	14
39	Patterns of Tumor Necrosis Factor Inhibitor (TNF i) Biosimilar Use Across United States Rheumatology Practices. <i>ACR Open Rheumatology</i> , 2020, 2, 79-83.	2.1	8
40	Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2020, 2, 53-60.	2.1	32
41	Reply. <i>Arthritis Care and Research</i> , 2020, 72, 736-738.	3.4	0
42	All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1457-1464.	3.4	9
43	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020, 2, 335-343.	2.1	131
44	Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. <i>RMD Open</i> , 2020, 6, e001321.	3.8	21
45	Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs. <i>ACR Open Rheumatology</i> , 2019, 1, 424-432.	2.1	39
46	Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 560-570.	2.1	11
47	Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1268-1280.	0.9	1
48	2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 1531-1539.	3.4	39
49	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. <i>Arthritis Care and Research</i> , 2019, 71, 1540-1555.	3.4	157
50	The Interface Between Digital Health and Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, xv-xvi.	1.9	0
51	Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. <i>RMD Open</i> , 2019, 5, e000935.	3.8	92
52	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019, 6, 409-419.	2.3	18
53	Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. <i>Arthritis Research and Therapy</i> , 2019, 21, 141.	3.5	43
54	Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 358-365.	3.4	56

#	ARTICLE	IF	CITATIONS
55	Medications associated with fracture risk in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1041-1047.	0.9	75
56	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Advances in Therapy</i> , 2019, 36, 1337-1357.	2.9	11
57	Mobile Apps for Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 197-209.	1.9	27
58	<p></p>Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 117-128.	1.9	7
59	Is It Time to Banish Composite Measures for Remission in Rheumatoid Arthritis?. <i>Arthritis Care and Research</i> , 2019, 71, 1300-1303.	3.4	5
60	SAT0377â€¦DIFFERENCES IN CLINICAL CHARACTERISTICS, QUALITY OF LIFE, DISABILITY, AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS PATIENTS BY GENDER: FINDINGS FROM A CROSS-SECTIONAL SURVEY IN THE US AND EUROPE. , 2019, , .		0
61	FRI0463â€¦ENTHESITIS, DACTYLITIS, AND AXIAL DISEASE IN PSORIATIC ARTHRITIS (PSA): IMPACT ON PATIENT QUALITY OF LIFE AND WORK PRODUCTIVITY. , 2019, , .		2
62	Response to: â€œMedications associated with fracture risk in patients with rheumatoid arthritisâ€™ by Chen et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216293.	0.9	2
63	OP0226â€¦SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
64	FRI0118â€¦INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
65	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	3.4	43
66	Correlation of the Multiâ€œBiomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Metaâ€œAnalysis. <i>Arthritis Care and Research</i> , 2019, 71, 1459-1472.	3.4	28
67	Allopurinol Dose Escalation and Mortality Among Patients With Gout. <i>Arthritis and Rheumatology</i> , 2018, 70, 1298-1307.	5.6	26
68	Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 548-554.	1.9	15
69	Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 203-209.	0.9	19
70	Malondialdehydeâ€œacetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions. <i>International Immunopharmacology</i> , 2018, 56, 113-118.	3.8	20
71	Using technology to support clinical care and research in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 276-281.	4.3	41
72	The impact of menopause on functional status in women with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 798-802.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Obesity, Weight Loss, and Progression of Disability in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 1740-1747.	3.4	22
74	Body Mass Index, Weight Loss, and Cause-Specific Mortality in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 11-18.	3.4	35
75	Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens. Arthritis Care and Research, 2018, 70, 533-541.	3.4	18
76	Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. Arthritis Care and Research, 2018, 70, 834-841.	3.4	5
77	Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis. Arthritis Care and Research, 2018, 70, 713-723.	3.4	15
78	Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival. Clinical Rheumatology, 2018, 37, 2907-2915.	2.2	19
79	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	2.5	9
80	The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 4-11.	0.9	23
81	A Mobile App With Optical Imaging for the Self-Management of Hand Rheumatoid Arthritis: Pilot Study. JMIR MHealth and UHealth, 2018, 6, e12221.	3.7	45
82	A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e84.	1.0	13
83	Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population. Arthritis Care and Research, 2017, 69, 338-346.	3.4	32
84	Response to: "Statin therapy now more common than steroids in clinical practice" by Pareek and Chankurdar. Annals of the Rheumatic Diseases, 2017, 76, e19-e19.	0.9	1
85	Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 848-854.	0.9	64
86	Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2017, 69, 1789-1798.	3.4	56
87	Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatology International, 2017, 37, 1551-1557.	3.0	313
88	Performance of the Patient-Reported Outcomes Measurement Information System 29-Item Profile in Rheumatoid Arthritis, Osteoarthritis, Fibromyalgia, and Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 1312-1321.	3.4	71
89	Modelling the cost-effectiveness of statin therapy in rheumatoid arthritis: a Markov-cycle evaluation from national data bank for rheumatic diseases. Journal of Pharmaceutical Health Services Research, 2017, 8, 139-145.	0.6	0
90	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	3.8	25

#	ARTICLE	IF	CITATIONS
91	Utilization of Care Outside the Veterans Affairs Health Care System by US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 776-782.	3.4	17
92	O09.â€fECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IS HIGHER FOR ANTI-CITRULLINATED PROTEIN ANTIBODY: POSITIVE PATIENTS. <i>Rheumatology</i> , 2017, 56, .	1.9	0
93	Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1089-1098.	5.6	83
94	Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2394-2402.	5.6	17
95	Changes in Body Mass Related to the Initiation of Diseaseâ€Modifying Therapies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1818-1827.	5.6	34
96	Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2016, 33, 1347-1359.	2.9	16
97	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1789-1796.	0.9	18
98	Patient-Reported Outcomes in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 219-237.	1.9	29
99	A PROMIS Measure of Neuropathic Pain Quality. <i>Value in Health</i> , 2016, 19, 623-630.	0.3	39
100	Causeâ€Specific Mortality in Male US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 36-45.	3.4	103
101	Rheumatology Informatics System for Effectiveness: A National Informaticsâ€Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016, 68, 1866-1873.	3.4	61
102	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	12.8	73
103	Increasing Public Health Burden of Arthritis and Other Rheumatic Conditions and Comorbidity: Results From a Statewide Health Surveillance System, 2007â€2012. <i>Arthritis Care and Research</i> , 2016, 68, 1417-1427.	3.4	13
104	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. <i>Arthritis Care and Research</i> , 2016, 68, 1478-1488.	3.4	54
105	Costâ€Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	3.4	27
106	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1797-1805.	0.9	16
107	The National Data Bank for Rheumatic Diseases (NDB). <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S100-S101.	0.8	13
108	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015, 1, e000155-e000155.	3.8	34

#	ARTICLE	IF	CITATIONS
109	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1121-1132.	1.9	6
110	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. <i>Arthritis Care and Research</i> , 2015, 67, 1637-1645.	3.4	16
111	Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1711-1717.	5.6	84
112	Impact of Total Knee Arthroplasty as Assessed Using Patient-Reported Pain and Health-Related Quality of Life Indices: Rheumatoid Arthritis Versus Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2503-2511.	5.6	37
113	Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: An observational cohort study. <i>International Immunopharmacology</i> , 2015, 24, 346-352.	3.8	28
114	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1640-1649.	1.9	13
115	Validation of the Rheumatic Disease Comorbidity Index. <i>Arthritis Care and Research</i> , 2015, 67, 865-872.	3.4	177
116	Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications. <i>Arthritis Care and Research</i> , 2014, 66, 1619-1626.	3.4	60
117	Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1935-1943.	2.0	25
118	Strong Association of Health Literacy With Functional Status Among Rheumatoid Arthritis Patients: A Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2014, 66, 508-514.	3.4	39
119	Rheumatoid Factor as a Potentiator of Anti-Citrullinated Protein Antibody-Mediated Inflammation in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 813-821.	5.6	174
120	Polysymptomatic Distress in Patients With Rheumatoid Arthritis: Understanding Disproportionate Response and Its Spectrum. <i>Arthritis Care and Research</i> , 2014, 66, 1465-1471.	3.4	43
121	Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. <i>Arthritis Research and Therapy</i> , 2013, 15, R195.	3.5	27
122	Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 227-234.	3.4	46
123	Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1498-1504.	2.0	7
124	Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 984-991.	2.8	60
125	Reply. <i>Arthritis Care and Research</i> , 2013, 65, 835-835.	3.4	2
126	Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 54-59.	2.0	51

#	ARTICLE	IF	CITATIONS
127	Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice. <i>Journal of Rheumatology</i> , 2012, 39, 1139-1145.	2.0	57
128	Impact of Total Shoulder Arthroplasty on Generic and Shoulder-Specific Health-Related Quality-of-Life Measures. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, e127.	3.0	105
129	Effect of body mass index on mortality and clinical status in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1471-1479.	3.4	108
130	Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 668-674.	3.4	132
131	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. <i>Arthritis Care and Research</i> , 2012, 64, 640-647.	3.4	566
132	Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients. <i>Arthritis Care and Research</i> , 2011, 63, 366-372.	3.4	37
133	Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. <i>Arthritis Research and Therapy</i> , 2011, 13, R168.	3.5	34
134	Mortality in fibromyalgia: A study of 8,186 patients over thirty-five years. <i>Arthritis Care and Research</i> , 2011, 63, 94-101.	3.4	93
135	Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality Measures of Rheumatoid Arthritis Disease Activity- Patient (PcGA) and Provider (PrGA) Global	3.4	223
136	Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5. <i>Arthritis Care and Research</i> , 2011, 63, S14-36.	3.4	202
137	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
138	Remission of rheumatoid arthritis in clinical practice: Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. <i>Arthritis and Rheumatism</i> , 2011, 63, 3204-3215.	6.7	75
139	The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. <i>Rheumatology</i> , 2011, 50, 16-24.	1.9	113
140	Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. <i>Rheumatology</i> , 2011, 50, 101-109.	1.9	80
141	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	3.4	161
142	Development and initial validation of a self-assessed lupus organ damage instrument. <i>Arthritis Care and Research</i> , 2010, 62, 559-568.	3.4	40
143	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2010, 62, 1481-1488.	3.4	34
144	The Hawthorne Effect, Sponsored Trials, and the Overestimation of Treatment Effectiveness. <i>Journal of Rheumatology</i> , 2010, 37, 2216-2220.	2.0	47

#	ARTICLE	IF	CITATIONS
145	Scale Characteristics and Mapping Accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1615-1625.	2.0	17
146	Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1292-1297.	0.9	86
147	EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, and Fibromyalgia. <i>Journal of Rheumatology</i> , 2010, 37, 296-304.	2.0	91
148	Chronic Conditions and Health Problems in Rheumatic Diseases: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, Systemic Lupus Erythematosus, and Fibromyalgia. <i>Journal of Rheumatology</i> , 2010, 37, 305-315.	2.0	123
149	The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. <i>Arthritis Research and Therapy</i> , 2010, 12, R35.	3.5	52
150	Proposed Metrics for the Determination of Rheumatoid Arthritis Outcome and Treatment Success and Failure. <i>Journal of Rheumatology</i> , 2009, 36, 27-33.	2.0	21
151	Outcome and Predictor Relationships in Fibromyalgia and Rheumatoid Arthritis: Evidence Concerning the Continuum versus Discrete Disorder Hypothesis. <i>Journal of Rheumatology</i> , 2009, 36, 831-836.	2.0	31
152	Predicting depression in rheumatoid arthritis: The signal importance of pain extent and fatigue, and comorbidity. <i>Arthritis and Rheumatism</i> , 2009, 61, 667-673.	6.7	160
153	Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1563-1570.	6.7	34
154	Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2009, 11, 229.	3.5	682
155	Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis. <i>Arthritis and Rheumatism</i> , 2008, 58, 939-946.	6.7	82
156	The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2612-2621.	6.7	142
157	Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study. <i>Arthritis and Rheumatism</i> , 2008, 59, 1090-1096.	6.7	104
158	The challenges of determining RA disease activity and remission in clinical practice. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 462-463.	3.2	5
159	The problem of rheumatoid arthritis disease activity and remission in clinical practice. <i>Journal of Rheumatology</i> , 2008, 35, 1015-22.	2.0	40
160	Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1023-30.	2.0	20
161	The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation. <i>Arthritis and Rheumatism</i> , 2007, 56, 1433-1439.	6.7	327
162	Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. <i>Arthritis and Rheumatism</i> , 2007, 56, 2135-2142.	6.7	113

#	ARTICLE	IF	CITATIONS
163	Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. <i>Arthritis and Rheumatism</i> , 2007, 56, 2886-2895.	6.7	498
164	Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 935-942.	6.7	54
165	Comorbidities in rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 885-906.	3.3	333
166	Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. <i>Journal of Rheumatology</i> , 2007, 34, 696-705.	2.0	77
167	Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. <i>Journal of Rheumatology</i> , 2007, 34, 1674-83.	2.0	109
168	The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. <i>Journal of Rheumatology</i> , 2007, 34, 2211-7.	2.0	46
169	Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2006, 54, 628-634.	6.7	422
170	Fibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteria. <i>Arthritis and Rheumatism</i> , 2006, 54, 169-176.	6.7	181
171	Anemia and renal function in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 1516-22.	2.0	44
172	Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. <i>Journal of Rheumatology</i> , 2006, 33, 1942-51.	2.0	111
173	Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 603-608.	6.7	62
174	The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes. <i>Arthritis and Rheumatism</i> , 2005, 52, 3873-3879.	6.7	58
175	Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 583-9.	2.0	50
176	Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. <i>Journal of Rheumatology</i> , 2005, 32, 1006-12.	2.0	59
177	Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1261-6.	2.0	24
178	Household income and earnings losses among 6,396 persons with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1875-83.	2.0	61
179	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	2.0	132
180	Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. <i>Journal of Rheumatology</i> , 2005, 32, 2130-5.	2.0	155

#	ARTICLE	IF	CITATIONS
181	A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). <i>Journal of Rheumatology</i> , 2005, 32, 2410-5.	2.0	88
182	Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. <i>Arthritis and Rheumatism</i> , 2004, 50, 372-379.	6.7	382
183	Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. <i>Arthritis and Rheumatism</i> , 2004, 50, 1740-1751.	6.7	787
184	Development and validation of the health assessment questionnaire II: A revised version of the health assessment questionnaire. <i>Arthritis and Rheumatism</i> , 2004, 50, 3296-3305.	6.7	231
185	Data collection, maintenance, and analysis for rheumatic disease research. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 753-768.	1.9	5
186	Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. <i>American Journal of Medicine</i> , 2004, 116, 305-311.	1.5	331
187	Rheumatoid arthritis and heart failure: The reply. <i>American Journal of Medicine</i> , 2004, 117, 709.	1.5	0
188	Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. <i>Journal of Rheumatology</i> , 2004, 31, 355-8.	2.0	15
189	Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. <i>Journal of Rheumatology</i> , 2004, 31, 695-700.	2.0	169
190	Predicting mortality in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1530-1542.	6.7	224
191	Direct medical costs and their predictors in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2750-2762.	6.7	238